ARTICLE | Clinical News
Aleglitazar: Development discontinued
July 15, 2013 7:00 AM UTC
Roche discontinued development of aleglitazar after an independent DSMB recommended stopping early the international Phase III AleCardio trial evaluating 150 µg once-daily aleglitazar due to "safety s...